---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-24-004479"
form_type: "8-K"
ticker: "CRVS"
cik: "0001626971"
company_name: "Corvus Pharmaceuticals, Inc."
filed_at: "2024-08-06T23:59:59+00:00"
generated_at: "2026-05-31T12:18:23.062410+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Corvus reports Q2 loss; soquelitinib shows early activity in atopic derm, PTCL Phase 3 on track

## Summary
- Early soquelitinib Phase 1 atopic dermatitis data (3 evaluable patients, 100 mg BID) show clinical activity and cytokine changes consistent with ITK inhibition.
- Phase 3 registrational trial for soquelitinib in PTCL to start Q3 2024; updated Phase 1/1b data: 39% ORR (6 CRs, 3 PRs) in 23 evaluable patients.
- Cash, cash equivalents and marketable securities $47.2M as of June 30, 2024; Q2 2024 net loss $4.3M vs $6.5M prior year; cash runway into Q4 2025.
- Ciforadenant Phase 1b/2 trial in RCC met interim efficacy threshold; enrollment continues. New U.S. patent issued for ciforadenant.
- Soquelitinib received Fast Track designation for relapsed/refractory PTCL; FDA pediatric waiver granted for T cell lymphoma indication.

## SEC filing metadata
- accession: 0001171843-24-004479
- form_type: 8-K
- ticker: CRVS
- cik: 0001626971
- company_name: Corvus Pharmaceuticals, Inc.
- filed_at: 2024-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1626971/000117184324004479/0001171843-24-004479-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1626971/000117184324004479/f8k_080624.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-24-004479
- JSON: https://secwatch.observer/filing/0001171843-24-004479.json
- Plain text: https://secwatch.observer/filing/0001171843-24-004479.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.